FNA - Paragon 28 Corp Total Debt to Capital

paragon28.com (FNA) - corporate logo

Paragon 28, Inc. (FNA) dominates the ankle fixation segment due to its wide selection of custom instruments and low demand elasticity. Patent protection and physician training create significant barriers to customer switching. This daily price chart reflects a total debt-to-equity ratio of 0.87, while business efficiency is supported by a streamlined express delivery system of sterile kits to operating rooms.

FNA: Paragon 28 Inc. Total Debt to Equity Ratio 07/04/2022 - 04/26/2025
Finished products of Paragon 28 Inc.

For Paragon 28, Inc. (FNA), financial stability is determined by the balance between liabilities and equity, which is critical when implementing costly ESG standards in implant production. Analyzing the debt-to-equity ratio at the level of 0.87, an investor can see the degree of leverage relative to the market value of assets, where an increase in the indicator signals elevated risks, while a decrease reflects the business's financial independence.

Competitor analysis

Debt to Equity Boston Scientific Corporation|Edwards - Aggregate Debt to Equity|Total Debt to Capital RMD|PODD - Debt to Capital|Total Debt to Capital ZBH (Zimmer Biomet Corp)|COO - Total Debt to Equity Ratio|Align Technology - Total Debt to Capital|Total Debt to Capital Coefficient Globus Medical Inc GMED|TMDX: Total Debt to Capital|Alphatec Corp (ATEC) - Total Debt to Capital|Debt to Equity Artivion, Inc.|Debt to Equity ENOV|Total Debt to Capital IART|Total Debt to Capital Coefficient Establishment Labs Corp|Beta Bionics Corp - Total Debt to Equity Ratio|IRMD (IRADIMED Inc.) - Aggregate Debt to Equity|Embecta Corp. - Total Debt to Capital|Debt to Capital tandemdiabetes.com|AXGN: Total Debt to Capital|Debt to Equity Ratio SIBN|Total Debt to Equity Ratio OFIX|BVS: All Debt to Shareholders' Equity Ratio|Debt to Equity OrthoPediatrics Corp. (KIDS)|Total Debt to Equity Ratio treace.com TMCI|Total Debt to Capital SRTA (Strata Critical Medical)|Carlsmed, Inc. (CARL) - Debt to Capital|RxSight Corp - Total Debt to Capital|CLPT (ClearPoint Neuro, Inc.) - Debt to Equity Ratio|STXS: Total Debt to Capital|STIM - Total Debt to Capital Coefficient|SGHT (Sight Sciences) - Total Debt to Capital|Total Debt to Equity Ratio Orchestra BioMed Inc. (OBIO)|Total Debt to Capital ANIK|Total Debt to Capital InspireMD Inc. (NSPR)|Debt to Equity Jin Medical ZJYL|Vivani Medical Inc - Debt to Equity|XTNT: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio NMTC (NeuroOne)|MODD: Total Debt to Capital|Debt to Capital Myomo Inc (MYO)|Debt to Equity Envoy Medical, Inc.|VVOS - Debt to Capital Ratio|Total Debt to Equity Ratio NVNO (enVVeno Medical Corp.)|Total Debt to Capital sintx.com (SINT)|Total Debt to Capital TNON (Tenon Medical, Inc)|Total Debt to Capital Coefficient Lifeward Ltd. (LFWD)|AMIX - Debt to Equity|Aggregate Debt to Equity IVF|Bone Biologics Corp (BBLG) - Debt to Equity|Total Debt to Equity Ratio Axonics Inc.|BIOL (Biolase, Inc.) - Total Debt to Capital|Debt to Capital Dynatronics Corp. DYNT|Debt to Equity INVO Bioscience, Inc. (INVO)